NATUS WEISSBLATT SOFTWARE

Under the terms of the merger agreement, Natus may solicit proposals from third parties for a period of 30 days continuing through May 17, 2022, and in certain cases for a period of 35 days continuing through May 22, 2022. Upon completion of the transaction, Natus will become a private company and Natus shares will no longer be listed on any public market. The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions, including approval by Natus shareholders and receipt of regulatory approvals. Natus expects to hold a Special Meeting of Shareholders to consider and vote on the proposed merger and the merger agreement as soon as practicable after the mailing of the proxy statement. Following any review by the SEC, a definitive proxy statement will be mailed to shareholders of Natus. Securities and Exchange Commission (“SEC”). In connection with the transaction, the Company will prepare a proxy statement to be filed with the U.S. Natus’s Board of Directors has unanimously approved the merger agreement with ArchiMed and recommends that Natus’s shareholders adopt the merger agreement. The transaction has fully committed equity financing from funds affiliated with ArchiMed and fully committed debt financing, and there are no financing conditions associated with the transaction. Under the terms of the agreement, Natus shareholders will receive $33.50 in cash for each share of Natus common stock they own. “ArchiMed’s mix of operational, medical, scientific and financial expertise will help us continue our mission to serve our customers while delivering immediate value to shareholders.” Sullivan, President & Chief Executive Officer of Natus Medical, Incorporated. “Our nearly 1,400 Natus Teammates remain committed to advance the standard of care and improve outcomes and quality of life for patients affected by disorders of the brain, neural pathways, and eight sensory nervous systems,” said Thomas J.

“The sale of Natus to ArchiMed will provide our shareholders with immediate and substantial cash value, as well as a compelling premium, and the Board has unanimously agreed that this transaction is in the best interests of our shareholders,” said Joshua H. Under the terms of the agreement, Natus shareholders will receive $33.50 in cash for each share of Natus common stock, representing a 29% premium to the closing price of the Company’s common stock on April 14, 2022. MIDDLETON, Wis., Ap(GLOBE NEWSWIRE) - Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that it has entered into a definitive agreement to be acquired by an affiliate of ArchiMed (“ArchiMed”), a leading investment firm focused exclusively on the healthcare industry for approximately $1.2 billion.

Pre-announces preliminary financial results for the first quarter ended March 31, 2022.Transaction values Natus Medical, Incorporated at approximately $1.2 billion total equity value.We are uniquely positioned to transform the treasure of data flowing through the vast Natus ecosystem into knowledge leading to innovation in the standard of care and new business opportunities. Our solutions create value for our customers and are valued by our customers making Natus globally #1, or #2 with a path to #1, in the markets in which we compete.

NATUS WEISSBLATT SOFTWARE

Natus is recognized by Healthcare Providers as the source for solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems.īest-in-class service and education complement hardware, advanced software and algorithms, and consumables that provide stimulus, acquire and monitor physiological signals, and capture how the body responds enabling clinicians to improve patient outcomes and quality of life.

Natus weissblatt